论文部分内容阅读
目的:评价头孢哌酮-舒巴坦对新生儿革兰阴性菌性败血症抗感染治疗的临床疗效。方法:选取2014年6月—2016年12月间新生儿科收治的革兰阴性菌性败血症新生儿64例,随机分为观察组及对照组,每组32例;对照组患儿给予氨曲南治疗,观察组患儿给予头孢哌酮-舒巴坦治疗,比较两组患儿治疗后的总有效率及安全性。结果:观察组患儿治疗后的总有效率为96.88%高于对照组为75.00%(P>0.05);观察组患儿用药期间肾毒性的发生率为3.13%稍低于对照组为25.00%(P<0.05),而不良反应的总发生率观察组低于对照组(P<0.05)。结论:对新生儿革兰阴性球菌性败血症采用头孢哌酮-舒巴坦治疗,临床疗效较为确切,用药期间出现的不良反应经对症处理后消失,用药安全性较高。
Objective: To evaluate the clinical efficacy of cefoperazone-sulbactam against neonatal Gram-negative bacterial sepsis. Methods: Sixty-four neonates with Gram-negative bacterial septicemia were enrolled in the Department of Neonatology from June 2014 to December 2016. They were randomly divided into observation group and control group, 32 cases in each group. The control group received aztreonam The treatment group and the observation group were given cefoperazone-sulbactam, and the total effective rate and safety of the two groups were compared. Results: The total effective rate of the observation group after treatment was 96.88% higher than that of the control group (75.00%) (P> 0.05). The incidence of nephrotoxicity in the observation group was 3.13% slightly lower than that in the control group (25.00% (P <0.05), while the overall incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05). Conclusion: Cefoperazone-sulbactam is effective in neonatal Gram-negative cocci sepsis. The clinical curative effect is relatively accurate. The adverse reactions disappeared after symptomatic treatment and the medication is safe.